FSZ - ETF AI Analysis
Top Page
First Trust Switzerland AlphaDEX Fund (FSZ)
FSZ, the First Trust Switzerland AlphaDEX Fund, earns a solid overall rating largely because several of its key holdings, like Sulzer AG and Swiss Re AG, show strong financial performance, reasonable valuations, and supportive technical trends that help underpin the fund’s quality. Additional contributors such as SFS Group AG and Emmi AG provide stable profitability and cash flow, while weaker names like SDZ and Avolta AG, which face valuation and profitability challenges along with bearish technical signals, modestly weigh on the rating. The main risk factor is the fund’s concentration in Swiss companies, which ties its fortunes closely to the economic and market conditions of Switzerland.
FSZ vs. SPDR S&P 500 ETF (SPY)
- AUM
- 37.00M
- Region
- Europe
- Expense Ratio
- 0.80%
- Beta
- 0.69
- Issuer
- First Trust
- Inception Date
- Feb 14, 2012
- Dividend Yield
- 2.00%
- Asset Class
- Equity
- Index Tracked
- NASDAQ AlphaDEX Switzerland Index
FSZ Summary
FSZ, the First Trust Switzerland AlphaDEX Fund, is an ETF that follows the NASDAQ AlphaDEX Switzerland Index, giving investors broad exposure to Swiss stocks. It focuses on a mix of different-sized companies across industries like industrials, finance, and consumer goods. Well-known holdings include Swiss Re, a major global reinsurer, and Swisscom, a leading telecom company. Someone might invest in FSZ to diversify into the Swiss and wider European market while seeking long-term growth from stable, innovative companies. A key risk is that the fund’s value can rise or fall with the Swiss stock market and currency movements.
How much will it cost me?
This ETF has an expense ratio of 0.80%, which means you’ll pay about $8 per year for every $1,000 you invest. That’s higher than the average ETF cost because it uses an actively managed, rules-based strategy (AlphaDEX) rather than a simple passive index approach.
What would affect this ETF?
FSZ could benefit from steady economic growth in Switzerland, strong performance in industrial and financial companies, and continued global demand for Swiss healthcare and consumer brands held in the fund. On the negative side, rising interest rates, a slowdown in European growth, currency swings in the Swiss franc, or new regulations affecting Swiss banks and insurers could weigh on the ETF’s future returns.
FSZ Top 10 Holdings
FSZ is essentially a bet on Switzerland’s industrial and financial backbone, with names like Sulzer and Swiss Re quietly powering the fund as their shares keep rising and sentiment stays upbeat. Health care and specialty manufacturing add some extra punch: Sandoz and Bachem have been climbing, though rich valuations mean they can wobble. VAT Group is more of a wild card, with mixed, recently lagging momentum despite strong longer-term gains. Overall, it’s a Switzerland-heavy, sector-diversified play, but with a clear tilt toward industrials and financials.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 CH:SUN | Sulzer AG | 5.58% | $1.95M | CHF 6.14B | 34.59% | 75Outperform |
 CH:SREN | Swiss Re AG | 4.93% | $1.72M | CHF 41.66B | 2.61% | 73Outperform |
 CH:SDZ | Sandoz Group Ltd | 4.64% | $1.62M | CHF 36.25B | 55.73% | 59Neutral |
 CH:VONN | Vontobel Holding AG | 4.06% | $1.42M | CHF 5.02B | 48.11% | 66Neutral |
 CH:SCMN | Swisscom AG | 3.71% | $1.29M | CHF 36.23B | 18.16% | 67Neutral |
 CH:BANB | Bachem Holding AG | 3.66% | $1.28M | CHF 6.30B | 43.06% | 64Neutral |
 CH:AVOL | Avolta AG | 3.61% | $1.26M | CHF 6.49B | 11.75% | 66Neutral |
 CH:EMMN | Emmi AG | 3.49% | $1.22M | CHF 4.98B | 28.24% | 71Outperform |
 CH:PSPN | PSP Swiss Property AG | 3.48% | $1.22M | CHF 6.97B | 8.81% | 72Outperform |
FSZ Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FSZ, the sentiment is Positive. The current price of 81.78 is above the 20-day moving average (MA) of 79.86, above the 50-day MA of 79.96, and above the 200-day MA of 80.90, indicating a bullish trend. The MACD of 0.58 indicates Negative momentum. The RSI at 62.08 is Neutral, neither overbought nor oversold. The STOCH value of 94.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FSZ.
FSZ Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| FSZ | $81.79 | $87.00(6.38% Upside) | $37.00M | 0.80% | 65Neutral |
 EWL | $64.37 | $66.87(3.88% Upside) | $3.01B | 0.50% | 71Outperform |
 FLEE | $38.08 | $45.01(18.19% Upside) | $99.74M | 0.09% | 64Neutral |
 FLSW | $44.40 | $46.49(4.72% Upside) | $92.69M | 0.09% | 70Neutral |
 FGM | $57.54 | $70.45(22.45% Upside) | $87.22M | 0.80% | 66Neutral |
 FLEU | $33.84 | $41.45(22.47% Upside) | $68.44M | 0.09% | 62Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FSZ | First Trust Switzerland AlphaDEX Fund | 81.78 | 7.99 | 10.83% | |
| EWL | iShares MSCI Switzerland ETF | 64.37 | 10.27 | 18.98% | |
| FLEE | Franklin FTSE Europe ETF | 38.08 | 4.51 | 13.42% | |
| FLSW | Franklin FTSE Switzerland ETF | 44.40 | 7.15 | 19.19% | |
| FGM | First Trust Germany AlphaDEX Fund | 57.54 | 0.82 | 1.45% | |
| FLEU | Franklin FTSE Eurozone ETF | 33.84 | 2.80 | 9.02% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.